EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 14c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $10.01 million versus the consensus estimate of $11.61 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• L3Harris CEO steps down amid conduct review, shares drop
• INVO Fertility (IVF) Tops Q2 EPS by 105c